2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1566 RAG1/RAG2 expression imbalance identifies high-risk pediatric B-cell acute lymphoblastic leukemia with features of developmental plasticity

Pablo Domizi, PhD, Cameron Baker, MS2, Tanxin Liu, MSc3, Milton Merchant4, Astraea Jager5, Yuxuan Liu, PhD6, Adam J de Smith, PhD7, Carol Fries Simpson, MD8, Kara L. Davis, D.O.9
1 Stanford University, Stanford, California, United States
2 University of Rochester, Rochester, New York, United States
3 University of Southern California, Los Angeles, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 University of Southern California, Los Angeles, California, United States
8 University of Rochester, Rochester, New York, United States
9 Stanford University, Stanford, California, United States

Background: RAG1 and RAG2 form the recombinase complex essential for V(D)J recombination during normal B-cell development. Their expression is tightly coordinated and restricted to developmental stages undergoing immunoglobulin heavy- and light-chain rearrangement. RAG1 recognizes recombination signal sequences (RSSs) and catalyzes DNA cleavage, whereas RAG2 binds histone H3 lysine 4 trimethylation (H3K4me3), promoting recombinase activity at transcriptionally active chromatin. Consequently, excess RAG2 relative to RAG1 may increase the potential for off-target recombinase activity at non-immunoglobulin loci, contributing to DNA double-strand breaks and genomic instability. Consistent with this mechanism, aberrant RAG-mediated recombination is a well-established driver of oncogenic alterations in B-cell acute lymphoblastic leukemia (B-ALL). However, whether disruption of RAG1/RAG2 stoichiometry has prognostic significance in B-ALL or defines a distinct leukemic cell state remains unknown.

Methods: To define physiologic RAG1/RAG2 expression, we analyzed publicly available single-cell RNA-sequencing datasets from human fetal (n=8) and adult (n=45) bone marrow. Leukemic RAG1/RAG2 expression was evaluated in two independent single-cell B-ALL cohorts comprising an internal University of Rochester Medical Center cohort (n=5) and the Pediatric Cancer Atlas (n=88). Cells were classified according to their RAG1/RAG2 expression ratio as RAG1-biased, RAG1-prone, concordant, RAG2-prone, or RAG2-biased. Differential gene expression and pathway enrichment analyses were performed using pseudobulk EdgeR/Limma models adjusted for patient identity and molecular subtype. Within the MP2PRT cohort, whole-genome sequencing data (n=1,493) were analyzed to identify off-target RAG-mediated structural variants (SVs), defined as non-Ig/TCR rearrangements harboring recombination signal sequence (RSS) motifs at breakpoint junctions. Clinical significance was evaluated in two independent pediatric B-ALL bulk RNA-seq cohorts (MP2PRT, n=1,451; TARGET, n=282). Patients were stratified into RAG2-biased, concordant, or RAG1-biased groups using the 25th and 75th percentiles of the RAG1/RAG2 ratio, and event-free survival (EFS) was assessed using subtype-adjusted Cox proportional hazards models.

Results: During normal B-cell development, RAG1 expression is higher across most developmental stages, whereas RAG2 predominance was largely restricted to the large pre-B stage. In contrast, leukemic B cells exhibited expanded populations of RAG2-biased cells spanning both large and small pre-B developmental states. Compared with RAG1-dominant cells, RAG2-biased and RAG2-prone leukemic cells were enriched for hematopoietic stem and progenitor cell transcriptional programs with reciprocal depletion of mature B-cell identity signatures, consistent with reduced B-lineage commitment and increased developmental plasticity. Consistent with this phenotype, decreasing RAG1/RAG2 ratios were associated with an increased burden of off-target RAG-mediated SVs, linking RAG2 predominance to heightened genomic instability. Clinically, patients who relapsed were more than twice as likely to exhibit RAG2-biased disease than non-relapsing patients (OR 2.24, 95% CI 1.73–2.90, P=3.98×10⁻¹⁰). Consistent with these findings, a low RAG1/RAG2 ratio (<Q25) independently predicted inferior event-free survival (EFS) in both the MP2PRT and TARGET cohorts (adjusted HR>1, P<0.05). Furthermore, high-risk molecular subtypes exhibited significantly lower RAG1/RAG2 ratios than favorable-risk subtypes.

Conclusions: An imbalanced RAG1/RAG2 expression ratio identifies a reproducible high-risk subgroup of pediatric B-ALL across two independent clinical cohorts. Single-cell transcriptomic analyses demonstrate that RAG2-dominant leukemic cells exhibit immature, progenitor-like programs consistent with increased developmental plasticity, while whole-genome sequencing links RAG2 predominance to increased off-target RAG-mediated genomic instability. Together, these findings establish the RAG1/RAG2 ratio as a robust prognostic biomarker and implicate disrupted recombinase stoichiometry as a potential driver of aggressive leukemia biology and adverse clinical outcomes.

Pablo Domizi, PhD: No relevant conflicts of interest to declare.